Sight Sciences Inc Stock

$2.61

1.14% today

Nasdaq, Feb 28, 05:17 pm CET

ISIN

US82657M1053

Symbol

SGHT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Medical specialties

Overview Dividends Analysts Charts News Strategies

Sight Sciences Inc Stock price

$2.64

-30.86 92.12% 5Y

Nasdaq, Closing price Thu, Feb 27 2025

-0.17 6.05%

ISIN

US82657M1053

Symbol

SGHT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Medical specialties

Key metrics

Market capitalization	$133.99m
Enterprise Value	$50.72m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	0.64
P/S ratio (TTM) P/S ratio	1.68
P/B ratio (TTM) P/B ratio	1.40
Revenue growth (TTM) Revenue growth	-3.99%
Revenue (TTM) Revenue	$79.54m
EBIT (operating result TTM) EBIT	$-49.71m
Free Cash Flow (TTM) Free Cash Flow	$-26.13m
Cash position	$118.56m
EPS (TTM) EPS	$-1.01
P/E forward	negative
P/S forward	1.67
EV/Sales forward	0.63
Short interest	3.24%

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Get Started for Free Today

Sight Sciences Inc Stock Analysis

Unlock Scores for Free

??

8 Analysts have issued a Sight Sciences Inc forecast:

2x Buy

25%

6x Hold

75%

More details on Analyst Estimates Including Price Targets

8 Analysts have issued a Sight Sciences Inc forecast:

Buy

25%

Hold

75%

Analyst Estimates with Stock Price Targets

Financial data from Sight Sciences Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Sep '24		+/- %
Revenue	80 80	4% 4% 100%
- Direct Costs	12 12	7% 7% 15%
Gross Profit	68 68	3% 3% 85%
- Selling and Administrative Expenses	100 100	12% 12% 125%
- Research and Development Expense	17 17	12% 12% 22%
EBITDA	-49 -49	21% 21% -62%
- Depreciation and Amortization	0.58 0.58	54% 54% 1%
EBIT (Operating Income) EBIT	-50 -50	21% 21% -63%
Net Profit	-50 -50	18% 18% -63%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Sight Sciences Inc Stock News

Neutral

GlobeNewsWire

●

4 days ago

Sight Sciences to Present Comprehensive Clinical Data on the OMNI® Surgical System at the 2025 American Glaucoma Society Annual Meeting

A Meta-Analysis of 22 Studies, and Data from the IRIS® Registry Highlighting Clinical Outcomes in Real-World Clinical Practice, Demonstrates Significant, Long-Term IOP Reduction and Medication Reduction with the OMNI® Surgical System

Neutral

GlobeNewsWire

●

9 days ago

Sight Sciences to Report Fourth Quarter and Full Year 2024 Financial Results on March 5, 2025

MENLO PARK, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today announced it will report financial results for the fourth quarter and full year ended December 31, 2024, after the...

Neutral

GlobeNewsWire

●

15 days ago

Sight Sciences to Present at Citi's 2025 Unplugged MedTech and Life Sciences Access Day

MENLO PARK, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced plans to present at Citi's 2025 Unplugged MedTech and Life Sciences Access Day, in New...

More Sight Sciences Inc News

Company Profile

Sight Sciences, Inc. is a medical device company, which engages in the provision of glaucoma implants for treatment of irreversible blindness. It also develops pharmaceuticals, drug delivery systems, and diagnostics for the treatment of ophthalmic conditions. The firms products include viscosurgical system and trabeculotomy instrument. It operates through the Surgical Glaucoma and Dry Eye segments. The Surgical Glaucoma segment includes OMNI Surgical System for use in minimally invasive glaucoma procedures. The Dry Eye segment offers TearCare System and related components. The company was founded by Paul Badawi and David Y. Badawi in 2011 and is headquartered in Menlo Park, CA.

Head office	United States
CEO	Paul Badawi
Employees	214
Founded	2011
Website	www.sightsciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now